Could a Low-Dose antipsychotic ease long COVID brain fog?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male, female or diverse adult who is 18 years or older at the time of informed consent * Potential participant is willing, understanding and able to provide informed consent * Signed informed consent prior to initiation of any trial-related measure * History of confirmed or suspected (PCR or serology or rapid antigen detection, certificate of attending physician, sick note) infectious disease * Ongoing symptoms of PAIS/PCC for ≥ 3 months * Self-reported neuropsychiatric symptoms at screening * For women of childbearing potential (WOCBP): 1. Confirmed post-menopausal state, defined as amenorrhea for at least 12 months, or 2. If being of childbearing potential: Negative highly sensitive urine or serum pregnancy test before randomization, and practicing a highly effective birth control method (failure rate of less than 1%) Exclusion Criteria: * Prior chronic neuroimmunological or neurodegenerative disease * Severe psychiatric disease (psychosis, bipolar disorder, severe major depression with inpatient treatment) within the last 10 years * Current malignant disease (including space-occupying brain tumors) * Concomitant antipsychotic medication * Patient is allergic or has contraindication to Aripiprazole or lactulose and cellulose * Patient is pregnant or breastfeeding * WOCBP who are unwilling to use an effective method of contraception as defined in inclusion criterion above * Bell disability scale \< 30 * Participation in another interventional clinical trial within the last 3 months or within five half-lives of the investigational product (whichever is longer) * Patient is institutionalized by order of court or public authority * Patient who might be dependent on the sponsor, the investigator or the trial site * Place of living does not allow the potential participant to attend the planned study visits * Other conditions that are likely to affect the safety of the study treatment (e.g. severely impaired immune status)